Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model (Q40191245)
Jump to navigation
Jump to search
scientific article published on 20 December 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model |
scientific article published on 20 December 2006 |
Statements
1 reference
Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model (English)
1 reference
Liang Zhang
1 reference
Xiaoping Zhang
1 reference
Glen W Barrisford
1 reference
Aria F Olumi
1 reference
20 December 2006
1 reference
1 reference
Identifiers
1 reference